<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587586</url>
  </required_header>
  <id_info>
    <org_study_id>A11-201</org_study_id>
    <nct_id>NCT01587586</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection</brief_title>
  <official_title>An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan: Food and Drug Administration, Department of Health, Executive Yuan</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:

      The purpose of this study is to determine and compare the sustained virologic response (SVR,
      undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.

      To determine and compare the safety and tolerability of P1101 + Ribavirin across treatment
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>Follow up week 24 across treatment groups</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with sustained virologic response (SVR, undetectable HCV RNA at follow up week 24) across treatment groups.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Pegasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegasys(subcutaneous injection)+Ribavirin, multiple doses(48)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 48 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)with Ribavirin, multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 24 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)+Ribavirin, multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 12 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)+Ribavirin, multiple doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>48 doses, solution, 48 weeks</description>
    <arm_group_label>Pegasys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 48 doses</intervention_name>
    <description>48 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 48 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 24 doses</intervention_name>
    <description>24 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 24 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 12 doses</intervention_name>
    <description>12 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 12 doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years of age ( ≥20 years for subjects enrolled in Taiwan);

          -  Confirmed diagnosis of chronic hepatitis C (CHC) virus genotype 1 infection;

          -  Compensated liver disease: with normal or elevated ALT/AST, no evidence of cirrhosis
             or portal hypertension as identified by ultrasound or any other procedures within 6
             months before study entry;

          -  Treatment naïve

          -  No other form of chronic liver disease apart from chronic hepatitis C infection;

          -  Hematology and renal biochemistry should be in definded ranges;

          -  Be able to attend all scheduled visits and to comply with all study procedures;

          -  Be able to provide written informed consent.

        Exclusion Criteria:

          -  Positive test for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus
             (HIV) at screening;

          -  Pregnancy or, in women of child-bearing potential or in spouses of such women,
             unwillingness or inability to practice adequate contraception;

          -  Inability to comprehend the written consent form;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting-Fang Wang, MS/MHA</last_name>
    <phone>+886 2 26557688</phone>
    <phone_ext>7814</phone_ext>
    <email>tingfang_wang@pharmaessentia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ching-Leou Teng, Ph.D.</last_name>
    <phone>+886 2 26557688</phone>
    <phone_ext>7801</phone_ext>
    <email>chingleou_teng@pharmaessentia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 27, 2012</lastchanged_date>
  <firstreceived_date>April 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Interferon-alpha</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
